The effects of administration of the Lactobacillus gasseri strain CP2305 on quality of life, clinical symptoms and changes in gene expression in patients with irritable bowel syndrome

Aims To clarify the effects of Lactobacillus gasseri CP2305 (CP2305) on quality of life and clinical symptoms and its functional mechanisms in patients with irritable bowel syndrome (IBS). Methods and Results After the patients were administered CP2305 daily for 4 weeks, the IBS‐severity index score...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of applied microbiology 2017-01, Vol.122 (1), p.212-224
Hauptverfasser:	Nobutani, K., Sawada, D., Fujiwara, S., Kuwano, Y., Nishida, K., Nakayama, J., Kutsumi, H., Azuma, T., Rokutan, K.
Format:	Artikel
Sprache:	eng
Schlagworte:	abdominal dysfunction Adult Female Gene expression Humans intestinal microbiota Irritable bowel syndrome Irritable Bowel Syndrome - drug therapy Irritable Bowel Syndrome - genetics Irritable Bowel Syndrome - metabolism Lactobacillus gasseri Lactobacillus gasseri - physiology Lactobacillus gasseri CP2305 leucocyte gene expression Male Microbiology Middle Aged probiotics Probiotics - administration & dosage Quality of Life Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!